JW Pharmaceutical Presents Research Results of Next-Generation Targeted Anticancer Drug 'JW-2286' at American Society of Clinical Oncology
Innovative New Drug Candidate with a Novel Mechanism for STAT3 Inhibition
[Asia Economy Reporter Kim Ji-hee] JW Pharmaceutical announced on the 29th that the research results of JW-2286, which targets STAT3, have been selected as an official presentation topic at the American Association for Cancer Research (AACR) Annual Meeting, held online from the 9th to the 14th of next month (local time).
The AACR is composed of over 40,000 cancer-related medical professionals and experts from the pharmaceutical and biotech industries worldwide. It holds an annual meeting to share the latest research information on cancer treatment, new anticancer drug development trends, and clinical results. Since last year, the event has been held online due to the impact of COVID-19.
JW-2286 (development code name) is an innovative new drug candidate with a novel mechanism that inhibits STAT3. It is indicated for solid tumors such as triple-negative breast cancer, gastric cancer, and colorectal cancer. STAT3 is a protein (transcription factor) that promotes the expression of numerous genes involved in cancer cell growth, proliferation, metastasis, and drug resistance formation. Although many studies have shown that inhibiting STAT3 is expected to have a powerful anticancer effect, there have been no successful cases worldwide in developing STAT3-targeted anticancer drugs.
JW Pharmaceutical plans to disclose data on the preclinical trial results of JW-2286 for the first time at this AACR Annual Meeting. Based on excellent selectivity for STAT3, JW-2286 demonstrated higher efficacy compared to existing standard therapies and safety for normal cells in various solid tumors with STAT3 activity as a biomarker.
In particular, the efficacy against triple-negative breast cancer will also be presented. Triple-negative breast cancer is a type of breast cancer that is not affected by hormone receptors (ER, PR) related to female hormones or epidermal growth factor receptor (HER2), representing an area with very high unmet medical needs.
A JW Pharmaceutical official stated, “Since STAT3 is known to be overexpressed in many tumors, promoting cancer growth and metastasis while suppressing antitumor immune responses, it has a very high potential for success as a cancer treatment target. This AACR presentation will serve as an opportunity to validate the competitiveness of JW-2286 targeting STAT3.”
Hot Picks Today
Taking Annual Leave and Adding "Strike" to Profiles, "It Feels Like Samsung Has Collapsed"... Unsettled Internal Atmosphere
- There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- "One Comment Could Lead to a Report": 86% of Elementary Teachers Feel Anxious; Half Consider Resignation or Career Change
- "After Vowing to Become No. 1 Globally, Sudden Policy Brake Puts Companies’ Massive Investments at Risk"
- On Teacher's Day, a Student's Gifted Cake Had to Be Cut into 32 Pieces... Why?
Meanwhile, JW Pharmaceutical acquired all rights to substances targeting STAT3 from its subsidiary JW C&C New Drug Research Institute in June last year and began full-scale commercialization. In December last year, it also signed a joint research agreement with the bio-venture company Voronoi to develop global anticancer drugs. This project aims to develop next-generation innovative new drugs by applying Voronoi’s proprietary protein degradation technology, PROTAC, to JW Pharmaceutical’s STAT3-targeted new drug candidates.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
